Latest Research Report on Breast Cancer Industry Identifying and Commercializing First-in-Class Innovation

1
Frontier Pharma Breast Cancer Identifying and
Commercializing First-in-Class Innovation- By
GBI Research
Published July 2014 No of Pages 116 Single
User PDF US 6995 Corporate User PDF US 20985

• View Complete Report _at_ http//www.lifescienceindus
  tryresearch.com/frontier-pharma-breast-cancer-iden
  tifying-and-commercializing-first-in-class-innovat
  ion.html .

2
Frontier Pharma Breast Cancer Identifying and
Commercializing First-in-Class Innovation
Exceptionally Large and Innovative Pipeline The
breast cancer pipeline is the largest in the
pharmaceutical industry with 815 products in
active development across all stages. The range
of mechanisms of action employed by these
compounds is also highly diverse, especially in
comparison to the existing market landscape. More
pertinently, the degree and proportion of
breakthrough innovations in this pipeline is
exceptional Researcher analysis identified 253
first-in-class programs in the breast cancer
pipeline, acting on 176 first-in-class molecular
targets. This accounts for some 39 of all
products with a disclosed molecular target and is
reflective of the high degree of innovation in
this indication. This has far-reaching strategic
implications for all market participants, as,
despite the high attrition rate in breast cancer,
it is highly likely many of the first-in-class
technologies will reach the market over the
coming decade and may transform the clinical and
commercial landscape. Alignment of First-in-Class
Molecular Target with Disease Causation One of
the key trends in oncology and in breast cancer
in particular over the last decade is the
clinical and commercial impact of targeted
therapies designed to target proteins in
signaling pathways that are frequently mutated in
a significant proportion of the patient
population. By aligning the molecular targets for
therapeutic intervention with disease causation
and/or propagation, these therapies limit the
systemic cytotoxic effects whilst inhibiting
tumor-promoting signaling pathways. Such
strategies thereby typically achieve superior
efficacy and safety profiles.
Buy a Copy of this Report _at_ http//www.lifescience
industryresearch.com/purchase?rname22893 .
3
Frontier Pharma Breast Cancer Identifying and
Commercializing First-in-Class Innovation

• Our proprietary analyses demonstrate significant
  levels of differentiation as to how well the
  first-in-class products and their respective
  molecular targets align to underlying gene and
  protein level mutations and dysfunction. More
  advanced analytics further substantiated these
  findings as strong levels of differentiation in
  the scientific and clinical rationale for
  first-in-class molecular targets emerged.
  Furthermore, clear frontrunners were identified
  by integrating analyses to assess the
  accessibility of molecular targets for
  therapeutic compounds, the size of the target
  patient population that would benefit from
  therapeutic intervention, and the expected
  positioning of the first-in-class products based
  on the molecular targets and mechanisms of action
  of currently marketed products.
• These insights and a detailed review of the
  available evidence from scientific studies
  substantiate the perspective that
  first-in-class-product technology in its own
  right is not sufficient to offer a compelling
  scientific and clinical rationale. However, a
  range of products offer very significant
  scientific and clinical promise and could
  therefore result in a strong commercial
  proposition with the prospect of clinically and
  commercially transformative products in the
  future.
• Single User License US 6995
• Inquire for a discount on this report _at_
  http//www.lifescienceindustryresearch.com/discoun
  t?rname22893 .

4
Frontier Pharma Breast Cancer Identifying and
Commercializing First-in-Class Innovation
A Highly Active Deals Landscape with Numerous
Investment Opportunities The breast cancer deals
landscape is highly dynamic, with both deal
number and aggregate value exceeding industry
benchmarks, reflecting the large and highly
competitive marketed and pipeline product
environments. Moreover, with 40 first-in-class
products that are currently in development having
been involved in a licensing or co-development
deal, the capital being committed to breast
cancer partnership deals is not limited to
products with established mechanisms of action in
the marketed product landscape. On the contrary,
breakthrough innovations are highly desirable as
an investment option. Analysis shows that the
licensing deal values can exceed the mean and
median deal values for licensing deals in Phase
I, II and III, suggesting that premium deals can
be achieved by smaller firms with the capacity to
advance strong products to one of the clinical
stages of development. However, most deals
involving first-in-class products were either
preclinical or Phase I development, whereas
advance-in-class and addition-to-class product
deals were typically made in Phases II and III,
therefore showing significant differentiation.
These findings have significant strategic
implications for both biotech companies seeking
to out-license products and firms with an
interest in in-licensing first-in-class products
with strong clinical and commercial
prospects. With the remaining 213 first-in-class
products that are currently in development having
not yet been involved in a licensing or
co-development deal, there are numerous
opportunities for in-licensing or co-development
in this indication, which already has a strong
track record of breakthrough innovation yielding
highly commercially and clinically successful
therapies. Although many act on targets that are
not yet strongly substantiated in terms of their
therapeutic potential in breast cancer in
clinical studies, there are many which are
supported by very robust and promising in vivo
and in vitro preclinical evidence, and as such
are highly promising breast cancer therapies.
Inquire Before Buying This Report _at_
http//www.lifescienceindustryresearch.com/inquire
-before-buying?rname22893 .
5
Frontier Pharma Breast Cancer Identifying and
Commercializing First-in-Class Innovation

• Scope
• The report analyzes innovation in breast cancer,
  in the context of the overall pipeline and
  current market landscape. In addition, it
  analyzed the deals landscape surrounding
  first-in-class products in breast cancer, and
  pinpoints opportunities for in-licensing. The
  report covers and includes
• A brief introduction to breast cancer, including
  symptoms, pathophysiology, and overview of
  pharmacotherapy and treatment algorithms.
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline.
• Comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of stage of development, molecule type and
  molecular target.
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews on novel molecular targets.
• Assessment of the licensing and co-development
  deal landscape for breast cancer therapies and
  benchmarking of deals involving first-in-class
  versus non-first-in-class-products.

Explore more reports on Pharmaceutical Market _at_
http//www.lifescienceindustryresearch.com/categor
y/pharmaceuticals .
6
Frontier Pharma Breast Cancer Identifying and
Commercializing First-in-Class Innovation

• Reasons to buy
• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to
• Understanding of the focal shifts in molecular
  targets in the breast cancer pipeline.
• Understanding of the distribution of pipeline
  programs by phase of development, molecule type
  and molecular target.
• Access a scientific and clinical analysis of
  first-in-class developmental programs for breast
  cancer, benchmarked against non-first-in-class
  targets.
• Assess the valuations of licensed and
  co-developed breast cancer treatments.
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities.

Buy a copy of this report _at_ http//www.lifescience
industryresearch.com/purchase?rname22893 .
7
About us Life Science Industry
Research brings to you to the latest reports in
market research on Biotechnology, Diagnostics,
Healthcare, Medical Devices and Pharmaceuticals
segments from leading research publishers across
the globe. These reports also cover data and
information on sub-segments and sectors under
these life sciences categories.Contact us
(sales_at_lifescienceindustryresearch.com / 1 888
391 5441) for any of your research requirements
or topics of interest. Our sales research
associates will be happy to help you find
relevant market data.Website
www.lifescienceindustryresearch.com
Browse Latest Industry News, Updates, Trends,
Opportunities, Scenario all over the world _at_